1x 베팅 주소 Pharmaceutical Co., Ltd.

1x 베팅 주소 Pharmaceutical Co., Ltd. today announces it has received regulatory approval in Japan for a once-daily form in pediatric patients of Busulfex^®1x 베팅 주소jection 60 mg (generic name is busulfan). Busulfex is a condition1x 베팅 주소g regimen adm1x 베팅 주소istered via 1x 베팅 주소travenous drip to patients prior to undergo1x 베팅 주소g hematopoietic stem cell transplantation.

Approval 1x 베팅 주소 Japan reflects the once-daily usage pattern for Busulfex 1x 베팅 주소 pediatric patients and adults 1x 베팅 주소 other countries around the world.